Skip to content
Politically.com Search all
Menu

Proposed rule 2026-19349

Nonclinical Testing Terminology

The Food and Drug Administration (FDA, Agency, or we) is proposing to substitute references to "animal" tests or studies with "nonclinical" tests or studies, add a definition of the terms "nonclinical test" and "nonclinical study," and make other comparable or conforming amendments in certain safety and reporting sections of its regulations. The proposed rule would also substitute "nonclinical" for "preclinical" and "in vitro" for consistency in terminology. These proposed amendments align with recent amendments to the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act) and are intended to remove an emphasis, in certain places, on the use of animal testing as the only scientific methodology to assess the safety of a drug in the nonclinical setting. These changes may also foster the development and use of scientifically valid new testing methodologies, potentially improving predictive accuracy of product safety testing while replacing, reducing, or refining animal use. The proposed rule would add no new requirements.

Source: FederalRegister.gov API v1Recently refreshed. Last successful refresh: 2026-09-22 18:49:02 UTC.

Source-supplied record

Document details

Document number
2026-19349
Published
Sep 22, 2026
Effective
Not supplied
Comments close
Dec 7, 2026 (open)
Federal Register citation
91 FR 60036

Docket identifiers

  • Docket No. FDA-2026-N-5347

CFR references

  • Title 21, part 312
  • Title 21, part 314
  • Title 21, part 315
  • Title 21, part 361
  • Title 21, part 601